Ask AI
MF Treatment Tool
Expert Guidance for the Selection of Systemic Agents in Myelofibrosis

Released: October 30, 2026

Instructions

This tool displays individual recommendations and comments from up to 5 experts for the patient characteristics entered. Have the relevant clinical and laboratory information available before beginning.


Questions vary by pathway. They may request blast percentage, risk group, transplant status, symptoms/splenomegaly, elevated blood counts, prior JAK inhibitor, platelet count, anemia/transfusion status, the reason for a treatment change, and serum EPO. EPO is not requested for a JAK inhibitor–naive patient without anemia or for a nonanemia reason for treatment change.


Click on your selections. Your choices can be changed at any time simply by selecting the [change] icon by the question you want to change and entering a new choice.


Additional information on each variable/characteristic and why it is important for making management decisions is available by clicking on the [i] icon after each selection.


When all patient characteristics are entered, you will be asked to select the management option you are currently planning. Once that information is entered, you can click on Submit Patient Case to view the expert recommendations.


After reviewing your case-specific recommendations, you will be asked brief questions about how the recommendations influenced your decision-making. You will then be able to enter a new case scenario by clicking the Start New Case button.


When viewing the tool online, the following functions are available:

  • Print/download the recommendations along with a summary of the patient characteristics and selected therapy you entered by clicking the Case Summary button


View the Additional Considerations section covering additional factors that may affect choice of therapy in MF.

Access to and use of the Interactive Decision Support Tool titled “Expert Guidance for Systemic Therapy in Myelofibrosis” are subject to the following terms and conditions.

Please read these terms carefully.

This tool educates healthcare professionals about management options for patients with MF. The recommendations reflect the individual expert guidance of John Mascarenhas, MD; Abdulraheem Yacoub, MD; Brady L. Stein, MD, MHS; Kristen Pettit, MD; and Raajit Rampal, MD, PhD. They do not establish a single preferred regimen or a panel consensus.


Materials published by Decera Clinical Education reflect the views of the authors or reviewers, rather than necessarily those of the educational provider or grant supporters. The activity may discuss uses or doses that are not approved by the FDA. Healthcare professionals should review the full current prescribing information, available evidence, and patient-specific factors before treatment.


Although this tool has been developed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of the information, individually or in aggregate. Decera Clinical Education provides this information on an as-is basis. All warranties, including merchantability, fitness for a particular purpose, freedom from computer viruses, and noninfringement of proprietary rights, are disclaimed.


Any trademarks are the property of their respective companies.

© 2026 Decera Clinical Education. All rights reserved.

Program Content